3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Neoplasms
10
Carcinoma, Renal Cell
8
Carcinoma, Hepatocellular
8
Melanoma
7
Carcinoma, Non-Small-Cell Lung
7
Endometrial Neoplasms
6
Thyroid Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
4
Thyroid Cancer, Papillary
3
Stomach Neoplasms
3
Neuroendocrine Tumors
3
Colorectal Neoplasms
3
Adenocarcinoma, Follicular
3
Ovarian Neoplasms
2
Osteosarcoma
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Glioma
2
Carcinoma, Transitional Cell
2
Carcinoma
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid cancer, medullary
1
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Thyroid Carcinoma, Anaplastic
1
Interventions
Nivolumab
4
pertuzumab
2
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Docetaxel
2
Capecitabine
2
ulocuplumab
1
tremelimumab
1
tazarotene
1
talazoparib
1
romiplostim
1
pexidartinib
1
pamiparib
1
onartuzumab
1
magrolimab
1
entrectinib
1
cobimetinib
1
atezolizumab
1
Sunitinib
1
Rifampin
1
Ramucirumab
1
Radiosurgery
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Midazolam
1
MK-4166
1
LY3022855
1
LY2510924
1
LY-2157299
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumor
×
lenvatinib
×
Clear all
No trials found.